Business Description
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide.
Website https://www.lexariabioscience.com/
FRC Analyst's Reports
This company was mentioned in the following "Analysts’ Ideas Of The Week":
This Producer is Acquiring a Gold Junior for <10% of Its NPV | Mar 6, 2023 |
Our Near-Term Outlook for the US$ and Metal Prices |
Feb 27, 2023 |
The Canadian Government Is Endorsing This Lithium Project |
Nov 28, 2022 |
Our Weekly Pick for Rising Global Tensions with Russia |
Oct 31, 2022 |
Mitsubishi Is Showing Interest in This Nickel Junior |
Aug 15, 2022 |
This is Very Positive for Uranium Juniors | Aug 2, 2022 |
The S&P 500 Has This Much Downside Risk | Jun 13, 2022 |
This Lithium Junior Continues to Return Highly Promising Results | Jun 7, 2022 |
These Two Crypto Platforms Could Be the Next M&A Targets | Apr 18, 2022 |
Our Last Week’s Pick Was Up 8% | Feb 8, 2022 |
Introducing Our 2022 Forecasts | Jan 4, 2022 |
This Nickel-Copper Junior Keeps Reporting High Values/Introducing Commentary on Cryptos | Oct 19, 2021 |
This Copper Junior is Getting No Value for Its Advanced Stage Flagship Asset | Oct 12, 2021 |
Reddit Moves to Uranium / Check Out Names Under Our Coverage | Sep 13, 2021 |